Viridian Therapeutics, Inc.\DE (VRDN) Consolidated Net Income: 2014-2025
Historic Consolidated Net Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$35.1 million.
- Viridian Therapeutics, Inc.\DE's Consolidated Net Income rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Consolidated Net Income is -$35.1 million, which was up 65.20% from -$100.7 million recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's Consolidated Net Income registered a high of -$14.0 million during Q3 2021, and its lowest value of -$100.7 million during Q2 2025.
- In the last 3 years, Viridian Therapeutics, Inc.\DE's Consolidated Net Income had a median value of -$66.9 million in 2023 and averaged -$66.4 million.
- Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Consolidated Net Income was 68.11% (2021), while the steepest drop was 177.41% (2021).
- Viridian Therapeutics, Inc.\DE's Consolidated Net Income (Quarterly) stood at -$28.9 million in 2021, then tumbled by 58.17% to -$45.8 million in 2022, then tumbled by 46.03% to -$66.9 million in 2023, then dropped by 19.33% to -$79.8 million in 2024, then skyrocketed by 54.18% to -$35.1 million in 2025.
- Its Consolidated Net Income was -$35.1 million in Q3 2025, compared to -$100.7 million in Q2 2025 and -$86.9 million in Q1 2025.